RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Jiangsu Ambition Medical has in-licensed China rights to a prostate treatment that is delivered via an injected depot system, which administers the drug directly to the tumor for up to six months. Sweden’s Lidds AB developed Liproca® Depot and is currently conducting a Phase IIb trial in Finland and Canada. Ambition will pay $1 million upfront, plus milestones and royalties for China rights. It will also be responsible for securing China regulatory approval, which may be the first approval for Liproca globally.
Source: China Biotoday
